share_log

君聖泰醫藥-B：截至二零二三年十二月三十一日止年度的全年業績公告

HIGHTIDE-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023

香港交易所 ·  Mar 27 06:55
Summary by Moomoo AI
君聖泰醫藥（「本公司」）公佈截至2023年12月31日止年度全年業績，顯示除稅前虧損及年內虧損分別為人民幣939,230千元及人民幣939,306千元，同比增加393.8%。經調整年內虧損淨額為人民幣288,443千元，同比增加56.9%。本公司於2023年12月22日在香港聯合交易所有限公司主板上市。全年業績反映了研發成本的增加，以及與上市相關的一次性開支。本公司專注於醫藥產品的研發，並已自主研發出一條包含5款專利候選藥物的管線，涵蓋9種適應症，其中5種處於臨床階段。展望未來，本公司將繼續通過臨床開發推動候選藥物管線，並尋求擴大管線的適應症覆蓋範圍。
君聖泰醫藥（「本公司」）公佈截至2023年12月31日止年度全年業績，顯示除稅前虧損及年內虧損分別為人民幣939,230千元及人民幣939,306千元，同比增加393.8%。經調整年內虧損淨額為人民幣288,443千元，同比增加56.9%。本公司於2023年12月22日在香港聯合交易所有限公司主板上市。全年業績反映了研發成本的增加，以及與上市相關的一次性開支。本公司專注於醫藥產品的研發，並已自主研發出一條包含5款專利候選藥物的管線，涵蓋9種適應症，其中5種處於臨床階段。展望未來，本公司將繼續通過臨床開發推動候選藥物管線，並尋求擴大管線的適應症覆蓋範圍。
JUN SHENG TAI PHARMACEUTICALS (THE “COMPANY”) ANNOUNCED ITS ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023, SHOWING THAT THE LOSS BEFORE TAX AND LOSS FOR THE YEAR WERE RMB939,230 THOUSAND AND RMB939,306 THOUSAND, RESPECTIVELY, AN INCREASE OF 393.8% YEAR-ON-YEAR. Adjusted net loss for the year was RMB288,443 thousand, an increase of 56.9% year-on-year. The Company was listed on the Main Board of the Hong Kong Stock Exchange Limited on 22 December 2023. The full year results reflect the increase in R&D costs, as well as the one-time costs associated with the listing. The company focuses on the development of medical products and has independently developed a pipeline of 5 patent candidates covering 9 indications, 5 of which are in the clinical stage. Looking ahead, the Company will continue to drive candidate drug pipelines through clinical development and seek to expand the pipeline's prescriptive coverage.
JUN SHENG TAI PHARMACEUTICALS (THE “COMPANY”) ANNOUNCED ITS ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023, SHOWING THAT THE LOSS BEFORE TAX AND LOSS FOR THE YEAR WERE RMB939,230 THOUSAND AND RMB939,306 THOUSAND, RESPECTIVELY, AN INCREASE OF 393.8% YEAR-ON-YEAR. Adjusted net loss for the year was RMB288,443 thousand, an increase of 56.9% year-on-year. The Company was listed on the Main Board of the Hong Kong Stock Exchange Limited on 22 December 2023. The full year results reflect the increase in R&D costs, as well as the one-time costs associated with the listing. The company focuses on the development of medical products and has independently developed a pipeline of 5 patent candidates covering 9 indications, 5 of which are in the clinical stage. Looking ahead, the Company will continue to drive candidate drug pipelines through clinical development and seek to expand the pipeline's prescriptive coverage.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more